Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Fast Is The Biosimilar Therapeutic Peptides Market Expected to Grow Between 2025 And 2029?

The market for biosimilar therapeutic peptides has seen substantial growth in recent years. The market value will rise from $2.06 billion in 2024 to $2.68 billion in 2025, experiencing a compound annual growth rate (CAGR) of 30.3%. This growth during the historic period can be credited to factors such as the rising demand for economical therapies, supportive regulatory structures and frameworks, expiration of patents for biologic drugs, increase in chronic disease occurence, and established manufacturing methodologies.

What Growth Rate Is Anticipated for the Biosimilar Therapeutic Peptides Market in the Coming Years?

The market size of biosimilar therapeutic peptides is projected to experience swift expansion in the forthcoming years, reaching $4.87 billion by 2029 with a compound annual growth rate (CAGR) of 16.1%. Contributions to this projected growth in the anticipated duration can be linked to escalating therapeutic applications, the worldwide aging populace, market competitiveness, strategic alliances and collaborations, alongside patient inclination for non-invasive treatments. Noteworthy trends during this forecast period encompass progress in biotechnology, a surge in demand for biologics, innovative developments in manufacturing, cost-efficiency focus and accessibility to healthcare, as well as technological progression.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3423&type=smp

Who Are the Leading Companies in the Biosimilar Therapeutic Peptides Market?

Major companies operating in the biosimilar therapeutic peptides market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceuticals Co. Ltd., Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, BioXpress Therapeutics SA, Apotex Inc., Teva Pharmaceuticals Industries Ltd., Sandoz International GmbH, Lonza Inc., Stada Arzneimittel AG, Ipsen S.A, Biocon Biopharmaceuticals Pvt. Ltd., Dr. Reddy’s Laboratories Ltd., Alvogen Pharma US Inc., Corden Pharma GmbH, Bachem Holding AG, PolyPeptide Laboratories Ltd., PeptiDream Inc., Coherus BioSciences Inc., Celltrion Inc., BioPartners Inc., Samsung Bioepis Co. Ltd.

What Are the Key Drivers of the Biosimilar Therapeutic Peptides Market?

The growth of the biosimilar therapeutic peptides market is likely to be fueled by the projected rise in elderly population numbers and a consequent increase in chronic disease patients. The likelihood of developing chronic conditions escalates with age, thus leading to a rapid increase in the elderly population worldwide, a trend expected to continue throughout the prediction period. Based on figures from the World Health Organization (WHO), it is anticipated that by 2050, the global population aged 60 and above will exceed 2 billion. The World Population Prospects further predict that the population of those aged 80 and above is set to surge from 143 million in 2019 to an impressive 426 million in 2050. Patient treatments for various chronic diseases and cancers commonly involve biosimilar therapeutic peptides, suggesting that the anticipated boom in the global aging population battling chronic diseases stands to stimulate the biosimilar therapeutic peptide market’s expansion.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=3423&type=smp

What Are the Key Market Segments in the Biosimilar Therapeutic Peptides Industry?

The biosimilar therapeutic peptides market covered in this report is segmented –

1) By Type: Innovative, Generic

2) By Route Of Administration: Parenteral Route, Transdermal Route, Other Route Of Administrations

3) By Application: Cancer, Cardiovascular, Central Nervous Systems, Metabolic Disorders, Infection, Hematological Disorders, Gastrointestinal Disorders, Dermatology, Respiratory Disorders

Subsegments:

1) By Innovative: Long-Acting Peptides, Combination Peptides

2) By Generic: Monoclonal Antibodies, Hormones, Enzymes

What Are the Latest Trends in the Biosimilar Therapeutic Peptides Market?

Key players in the biosimilar therapeutic peptide marketplace are diligently working on research platforms aimed at refining peptide synthesis, boosting production efficiency and ensuring consistent quality throughout the journey from discovery to market-readiness. The Biodrug Design Accelerator is one such platform being utilized to streamline the research process in peptide drug discovery, an area seen by many as a cutting-edge sector in novel drug development. An example of this was in May 2023 when the US-based toy production and entertainment firm, Fujitsu Limited, introduced the Biodrug Design Accelerator platform to expedite research into peptide drug discovery. The Biodrug Design Accelerator aims to support scientists in the pharmaceutical industry engaged in peptide drug discovery, by accelerating and enhancing the efficacy of peptide drug development. This is particularly achieved through the design, make, test, analyze (DMTA) cycles, which ultimately results in faster and more informed design of peptide drug contenders and also remarkably improves communication between scientists about synthesis and testing processes.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/biosimilar-therapeutic-peptide-global-market-report

What Are the Key Regional Markets in the Biosimilar Therapeutic Peptides Industry?

The countries covered in the biosimilar therapeutic peptides market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3423

This Report Delivers Insight On:

1. How big is the biosimilar therapeutic peptides market, and how is it changing globally?

2. Who are the major companies in the biosimilar therapeutic peptides market, and how are they performing?

3. What are the key opportunities and risks in the biosimilar therapeutic peptides market right now?

4. Which products or customer segments are growing the most in the biosimilar therapeutic peptides market?

5. What factors are helping or slowing down the growth of the biosimilar therapeutic peptides market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model